# Component for Institution # 264313

> **NIH NIH P30** · TEMPLE UNIV OF THE COMMONWEALTH · 2024 · $223,133

## Abstract

The Integrated Physiological Systems and Pain (IPSP) Core, formerly known as the Integrative
Pharmacology Core, provides pharmacological testing, scientific expertise, and related resources to
advance research productivity and spark new areas of scientific discovery in substance abuse
research. The NIDA P30 Center has a rich history in supporting interdisciplinary projects from
established and new investigators, both at Temple University and outside of Temple, that have created
synergy among scientists from different disciplines and linked drug addiction research to disorders such
as pain and HIV. In this 5-year renewal application, the main themes that will be pursued are: (1)
opioids, especially in the context of separating therapeutic (e.g. analgesic) and adverse (e.g.
dependence, tolerance, respiratory depression, constipation) effects; (2) interactions between
substance abuse and HIV in animal models, especially as related to how psychostimulant and opioid
exposure impacts HIV Infectivity, replication, and latency and how HIV infection impacts opioid
dependence and analgesia; and (3) crosstalk between neuroimmune and brain reward systems,
especially in the context of identifying and characterizing neuroimmune biomarkers (e.g. chemokines,
cytokines) of drug addiction and investigating neuroimmune-based therapeutic approaches for
substance abuse. Additional emphasis will be placed on supporting drug discovery projects with high
translational potential such as characterization of bifunctional NOP-MOP (nociception opioid receptor-
mu opioid receptor) agonists, GPR55 ligands, and chemokine receptor antagonists. In terms of
prioritizing projects, and aligning with NIH goals of enhancing investigator diversity, efforts will be made
to support early career investigators and investigators from populations underrepresented in the
biomedical sciences. To expand the impact of NIH-funded research projects related to NIDA's mission
through national collaborations, the implementation of innovative methodology is proposed that will
enable assessment of three new physiological endpoints: (1) in vivo neuronal activity using miniaturized
fluorescence microscopy; (2) respiratory depression for assessment of adverse opioid effects; and (3)
chemotherapy-induce neuropathic pain to screen novel experimental compounds for neuroprotective
and analgesic efficacy. The expected positive impact of the collaborations proposed by the IPSP Core,
through significant interactions with the other Research Support Cores of the NIDA P30 Center, is
facilitation of hypothesis-driven, translational research that links drug addiction to pathologies including
HIV and pain.

## Key facts

- **NIH application ID:** 10839857
- **Project number:** 5P30DA013429-25
- **Recipient organization:** TEMPLE UNIV OF THE COMMONWEALTH
- **Principal Investigator:** SCOTT M. RAWLS
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $223,133
- **Award type:** 5
- **Project period:** 2000-09-30 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10839857

## Citation

> US National Institutes of Health, RePORTER application 10839857, Component for Institution # 264313 (5P30DA013429-25). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10839857. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*